Analysts expect CTI BioPharma Corp. (NASDAQ:CTIC) to report $-0.30 EPS on March, 1.They anticipate $0.07 EPS change or 30.43% from last quarter’s $-0.23 EPS. After having $-0.28 EPS previously, CTI BioPharma Corp.’s analysts see 7.14% EPS growth. The stock increased 3.43% or $0.11 during the last trading session, reaching $3.32. About 633,711 shares traded or 123.43% up from the average. CTI BioPharma Corp. (NASDAQ:CTIC) has declined 4.09% since February 13, 2017 and is downtrending. It has underperformed by 20.79% the S&P500.
ESSENTIAL ENERGY SERIES (OTCMKTS:EEYUF) had an increase of 123.44% in short interest. EEYUF’s SI was 42,900 shares in February as released by FINRA. Its up 123.44% from 19,200 shares previously. With 3,000 avg volume, 14 days are for ESSENTIAL ENERGY SERIES (OTCMKTS:EEYUF)’s short sellers to cover EEYUF’s short positions. The stock increased 6.47% or $0.0335 during the last trading session, reaching $0.5515. About shares traded. Essential Energy Services Ltd. (OTCMKTS:EEYUF) has 0.00% since February 13, 2017 and is . It has underperformed by 16.70% the S&P500.
Essential Energy Services Ltd., together with its subsidiaries, provides oilfield services to gas and oil exploration and production companies primarily in western Canada. The company has market cap of $77.34 million. The firm operates through two divisions, Essential Coil Well Service and Downhole Tools & Rentals. It currently has negative earnings. The Essential Coil Well Service segment offers well completion, and production and workover services through its fleet of coil tubing rigs, service rigs, fluid and nitrogen pumpers, and ancillary equipment.
Among 2 analysts covering CTI BioPharma Corp (NASDAQ:CTIC), 1 have Buy rating, 0 Sell and 1 Hold. Therefore 50% are positive. CTI BioPharma Corp had 3 analyst reports since August 15, 2015 according to SRatingsIntel. The stock of CTI BioPharma Corp. (NASDAQ:CTIC) earned “Hold” rating by WallachBeth Capital on Monday, November 9. The company was maintained on Saturday, August 15 by Roth Capital.
CTI BioPharma Corp., a biopharmaceutical company, engages in the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States and internationally. The company has market cap of $142.71 million. It primarily focuses on the commercialization of PIXUVRI, an aza-anthracenedione for the treatment of adult patients with multiply relapsed or refractory aggressive B-cell non-Hodgkin lymphoma in the European Union. It currently has negative earnings. The firm is also developing Pacritinib, an investigational oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R, which is in Phase Phase III clinical trials for the treatment of myelofibrosis.